LONDON – Ocata Therapeutics Inc. is poised to start phase II trials of its human embryonic stem cell-derived retinal pigment epithelium (RPE) cells in the treatment of macular degeneration, which the company said will be the first such ophthalmic studies to feature placebo-controlled arms.